SpringLeaf Therapeutics is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf’s technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including SR One, Flybridge Capital Partners and North Bridge Venture Partners. For more information, visit www.springleaftx.com.
Company Details
- Founded
- -
- Address
- Serious Disease And Elevate The Quality Of Care For Patients. Springleaf’s Technology Is Based On The Convergence Of Materials Science And Medicine And Is Designed To Enable And Differentiate Therapeutics. Springleaf Was Founded Based On Breakthrough Science At Mit And Is Backed By Leading Investors Including Sr One
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.springleaftx.com
- Keywords
- actnano.
Springleaf Therapeutics Questions
Springleaf Therapeutics's website is http://www.springleaftx.com
Springleaf Therapeutics's LinkedIn profile is https://www.linkedin.com/company/springleaf-therapeutics
Springleaf Therapeutics's industry is
Biotechnology Research
Springleaf Therapeutics's top competitors are
Womxn For Climate Tech & Innovation,
Bell International Laboratories,
Actnano,
Gelmedix,
Via Separations,
Terragia Biofuel,
Foodberry,
Complexity Science Hub,
Verdox,
Virex Health.
Springleaf Therapeutics's categories are Biotechnology Research
Springleaf Therapeutics's founding year is 2007
